Mantovani A, Dalbeni A. Recent Developments in NAFLD. Int J Mol Sci. 2022;23:2882.
PubMed PubMed Central Article Google Scholar
Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD. Hepatology. 2020;72:1605–16.
Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62:S47–64.
Eslam M, George J. MAFLD: now is the time to capitalize on the momentum. J Hepatol. 2021;74:1262–3.
Petäjä EM, Yki-Järvinen H. Definitions of Normal liver fat and the Association of Insulin Sensitivity with acquired and genetic NAFLD-A systematic review. Int J Mol Sci. 2016;17:633.
PubMed Central Article CAS Google Scholar
Carr RM, Oranu A, Khungar V. Nonalcoholic fatty liver disease. Gastroenterol Clin N Am. 2016;45:639–52.
Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908–22.
CAS PubMed PubMed Central Article Google Scholar
Leite NC, Villela-Nogueira CA, Cardoso CR, Salles GF. Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment. World J Gastroenterol. 2014;20:8377–92.
PubMed PubMed Central Article CAS Google Scholar
Stefan N, Häring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019;7:313–24.
Muzurović E, Mikhailidis DP, Mantzoros C. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. METABOLISM. 2021;119:154770.
PubMed Article CAS Google Scholar
Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in nonalcoholic fatty liver disease. Metabolism. 2016;65:1062–79.
CAS PubMed Article Google Scholar
Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med. 2009;9:299–314.
CAS PubMed Article Google Scholar
Polyzos SA, Aronis KN, Kountouras J, Raptis DD, Vasiloglou MF, Mantzoros CS. Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia. 2016;59:30–43.
CAS PubMed Article Google Scholar
Hu J, Ke Y, Wu F, Liu S, Ji C, Zhu X, et al. Circulating Irisin levels in patients with nonalcoholic fatty liver disease: a systematic review and Meta-analysis. Gastroenterol Res Pract. 2020;2020:8818191.
PubMed PubMed Central Article Google Scholar
Kurowska P, Mlyczyńska E, Dawid M, Jurek M, Klimczyk D, Dupont J, et al. Review: Vaspin (SERPINA12) expression and function in endocrine cells. Cells. 2021;10:1710.
CAS PubMed PubMed Central Article Google Scholar
Escoté X, Gómez-Zorita S, López-Yoldi M, Milton-Laskibar I, Fernández-Quintela A, Martínez JA, et al. Role of Omentin, Vaspin, Cardiotrophin-1, TWEAK and NOV/CCN3 in obesity and diabetes development. Int J Mol Sci. 2017;18:1770.
PubMed Central Article CAS Google Scholar
Rashad NM, Ahmed HS, Ashour W, Yousef MS. Association of vaspin gene expression and its serum level on the risk of ischemic stroke in type 2 diabetic Egyptian patients: prospective case-control study. Biotechnol Appl Biochem. 2020;67:912–9.
CAS PubMed Article Google Scholar
Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160.
PubMed PubMed Central Article Google Scholar
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5.
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–74.
CAS PubMed Article Google Scholar
Schmidt FL, Oh IS, Hayes TL. Fixed- versus random-effects models in meta-analysis: model properties and an empirical comparison of differences in results. Br J Math Stat Psychol. 2009;62:97–128.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.
PubMed PubMed Central Article Google Scholar
Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.
CAS PubMed PubMed Central Article Google Scholar
Ismail SM, Elgendy NA, Sayed ZH, Hameed AA, Ahmad IH, Althoqapy AA. Chemerin and vaspin as noninvasive biomarkers in the pathogenesis and diagnosis of non-alcoholic fatty liver disease. Am J Med Med Sci. 2019;9:7–13.
Aktas B, Yilmaz Y, Eren F, Yonal O, Kurt R, Alahdab YO, et al. Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease. Metabolism. 2011;60:544–9.
CAS PubMed Article Google Scholar
Fu SJ, Yang ZX. Correlation between serum HMGB-1, IL-1β, Vaspin levels and HOMA-IR in patients with nonalcoholic fatty liver disease. Int J Lab Med. 2019;40(2132–2134):2138.
Genc H, Dogru T, Tapan S, Kara M, Ercin CN, Aslan F, et al. Circulating vaspin and its relationship with insulin sensitivity, adiponectin, and liver histology in subjects with non-alcoholic steatohepatitis. Scand J Gastroenterol. 2011;46:1355–61.
CAS PubMed Article Google Scholar
Kukla M, Zwirska-Korczala K, Hartleb M, Waluga M, Chwist A, Kajor M, et al. Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scand J Gastroenterol. 2010;45:235–42.
CAS PubMed Article Google Scholar
Montazerifar F, Bakhshipour AR, Karajibani M, Torki Z, Dashipour AR. Serum omentin-1, vaspin, and apelin levels and central obesity in patients with nonalcoholic fatty liver disease. J Res Med Sci. 2017;22:70.
PubMed PubMed Central Article Google Scholar
Polyzos SA, Kountouras J, Polymerou V, Papadimitriou KG, Zavos C, Katsinelos P. Vaspin, resistin, retinol-binding protein-4, interleukin-1α and interleukin-6 in patients with nonalcoholic fatty liver disease. Ann Hepatol. 2016;15:705–14.
Su XL, Wang TS, Zhang YJ. Expression and significance of serum Omentin-1 and vaspin in patients with nonalcoholic fatty liver disease. Liver. 2021;26:67–70.
Waluga M, Kukla M, Kotulski R, Zorniak M, Boryczka G, Kajor M, et al. Omentin, vaspin and irisin in chronic liver diseases. J Physiol Pharmacol. 2019;70:277.
Xia W, Wen SL, Zhang L, Jia HY. Changes in Vaspin levels in elderly patients with type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease. Chinese J Diabetes. 2011;19:691–4.
Yan LL, Lu J, Jia HY. Serum Chemerin, Vaspin and TXNIP levels in patients with non-alcoholic fatty liver disease and their correlation analysis. Guizhou Med J. 2019;43:364–6.
Yilmaz Y, Kurt R, Gurdal A, Alahdab YO, Yonal O, Senates E, et al. Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary flow reserve in patients with nonalcoholic fatty liver disease. Atherosclerosis. 2011;217:125–9.
CAS PubMed Article Google Scholar
Yu HY, Di FS, Wang L, Li Q, Jia GY, Zhang J, et al. Correlation between plasma Vaspin and metabolic parameters in diabetic patients with fatty liver. Tianjin Med J. 2012;40:1121–4.
Younossi ZM. Non-alcoholic fatty liver disease - a global public health perspective. J Hepatol. 2019;70:531–44.
Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–57.
Schattenberg JM, Schuppan D. Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic. Curr Opin Lipidol. 2011;22:479–88.
CAS PubMed Article Google Scholar
Schuppan D, Schattenberg JM. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol. 2013;28(Suppl 1):68–76.
CAS PubMed Article Google Scholar
Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A. 2005;102:10610–5.
留言 (0)